APOE: A potential marker of disease progression in ALS

被引：60
|
作者：
Lacomblez, L
Doppler, V
Beucler, I
Costes, G
Salachas, F
Raisonnier, A
Le Forestier, N
Pradat, PF
Bruckert, E
Meininger, V
机构：
[1] Hop La Pitie Salpetriere, AH HP, Federat Neurol Mazarin, F-75013 Paris, France
[2] Hop La Pitie Salpetriere, AH HP, Serv Pharmacol, F-75013 Paris, France
[3] Hop La Pitie Salpetriere, AH HP, Serv Endocrinol, F-75013 Paris, France
[4] Hop La Pitie Salpetriere, AH HP, Lab Lipides & Lipoprot, F-75013 Paris, France
来源：
NEUROLOGY | 2002年 / 58卷 / 07期
关键词：
D O I：
10.1212/WNL.58.7.1112
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Although documented in AD, the role of APOE remains unclear in ALS. APOE phenotype and plasma levels were measured in 403 patients with ALS and were cor related with clinical parameters and survival time. No correlations were observed between the APOE phenotype, and these variables. In contrast, APOE plasma levels were correlated with both rate of deterioration and survival time and appeared to be an important risk factor for decreased survival time with a relative risk of 0.647 (95% Cl: 0.465 to 0.901; P = 0.01).
引用
收藏
页码：1112 / 1114
页数：3
相关论文
共 50 条
  • [1] Potential Immune Biomarkers for Disease Progression in ALS
    Zhao, Weihua
    Beers, David
    Thonhoff, Jason
    Neal, Dan
    Wen, Shixiang
    Wang, Jinghong
    Appel, Stanley
    NEUROLOGY, 2016, 86
  • [2] Sudoscan in ATTRv Amyloidosis: A Potential Marker of Disease Progression?
    Romano, Angela
    Guglielmino, Valeria
    Vitali, Francesca
    Sciarrone, Maria Ausilia
    Siconolfi, Giovanni
    Di Paolantonio, Andrea
    Primiano, Guido
    Luigetti, Marco
    NEUROLOGY AND THERAPY, 2025,
  • [3] Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression
    Dysli, Chantal
    Wolf, Sebastian
    Hatz, Katja
    Zinkernagel, Martin S.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (03) : 832 - 841
  • [4] Toward a surrogate marker of disease progression in ALS using 1H MRSI
    Weiner, MW
    Rooney, WD
    Schuff, N
    Maudsley, A
    Gelinas, DF
    Miller, RG
    NEUROLOGY, 1997, 48 (03) : 29003 - 29003
  • [5] Biomarkers for ALS disease progression
    Bowser, Robert
    Ryberg, Henrik
    Darko, Sam
    An, Jiyan
    Wilsoni, Meghan
    Lacomis, David
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2008, 67 (05): : 499 - 499
  • [6] Biomarkers for ALS disease progression
    Bowser, Robert
    Ryberg, Henrik
    Darko, Sam
    An, Jiyan
    Wilson, Meghan
    Lacomis, David
    FASEB JOURNAL, 2008, 22
  • [7] Pinpointing disease progression in ALS
    不详
    MEDICAL JOURNAL OF AUSTRALIA, 2022, 216 (02) : 59 - 59
  • [8] A protein biomarker analysis of Peyronie's disease: potential marker of disease progression?
    Chung, E.
    De Young, L.
    O'Gorman, D. B.
    Brock, G. B.
    BJU INTERNATIONAL, 2012, 109 : 51 - 51
  • [9] CMAP decrement as a potential diagnostic marker for ALS
    Mori, A.
    Yamashita, S.
    Nakajima, M.
    Hori, H.
    Tawara, A.
    Matsuo, Y.
    Misumi, Y.
    Ando, Y.
    ACTA NEUROLOGICA SCANDINAVICA, 2016, 134 (01): : 49 - 53
  • [10] Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease
    Vinther-Jensen, T.
    Simonsen, A. H.
    Budtz-Jorgensen, E.
    Hjermind, L. E.
    Nielsen, J. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 (10) : 1380 - 1386
12345